Dermata Therapeutics (DRMA) vs Lunai Bioworks (LNAI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Dermata Therapeutics is the larger company by market cap ($5.3 million vs $5.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | DRMA | LNAI |
|---|---|---|
| Share price | $1.07 | $1.14 |
| Market cap | $5.30M | $5.17M |
| 1-day change | -4.46% | +4.59% |
| EPS (TTM) | $-4.39 | $-61.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.84 | $13.28 |
| 52-week low | $0.951 | $1.08 |
| Distance from 52-week high | -77.89% | -91.42% |
| Average volume | 708.18K | 181.37K |
| Shares outstanding | 4.96M | 4.53M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
DRMA vs LNAI FAQ
Which is bigger, Dermata Therapeutics or Lunai Bioworks?
Dermata Therapeutics (DRMA) is larger, with a market capitalization of $5.30M compared with $5.17M for Lunai Bioworks (LNAI).
Are Dermata Therapeutics and Lunai Bioworks in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.